Molbio Diagnostics has 6 close competitors: Pristyn Care, Abridge, Alloy Therapeutics.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
Molbio DiagnosticsPristyn CareAbridgeBenchlingCMR SurgicalCommureIndian molecular diagnostics company that developed the Truenat portable real-time PCR platform used to detect infectious diseases such as tuberculosis, HIV and hepatitis.
Molbio Diagnostics competes with 6 companies here: Pristyn Care, Abridge, Alloy Therapeutics, Benchling, CMR Surgical, Commure.
Molbio Diagnostics was last valued at $1B (post-money, Jan 2022). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The closest medical diagnostics / molecular diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. Molbio Diagnostics is listed on BSE/NSE as MOLBIO.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
